TRIP13 expression levels were negatively associated with immunocyte infiltration, immune scores, tumor mutational burden, microsatellite instability, and DNA methylation in certain cancers, and positively correlated with the expression of at least 5 immune checkpoint-related genes in bladder carcinoma, breast cancer, kidney clear cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, mesothelioma, and thyroid cancer. Here, TRIP13 is linked to cancer.